These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1875784)

  • 1. Vasorelaxant effect of C16-PAF and C18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat.
    Handa RK; Strandhoy JW; Buckalew VM
    Life Sci; 1991; 49(10):747-52. PubMed ID: 1875784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-activating factor is a renal vasodilator in the anesthetized rat.
    Handa RK; Strandhoy JW; Buckalew VM
    Am J Physiol; 1990 Jun; 258(6 Pt 2):F1504-9. PubMed ID: 2360650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Nitric oxide in the renal and systemic vasodilatory responses to platelet-activating factor in the rat, in vivo.
    Handa RK; Strandhoy JW; Handa SE
    Kidney Blood Press Res; 2003; 26(3):165-75. PubMed ID: 12886044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of vasoconstrictor responses by platelet-activating factor in rat kidney.
    Handa RK; Strandhoy JW; Buckalew VM
    Am J Physiol; 1991 Jul; 261(1 Pt 2):F108-16. PubMed ID: 1907104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet activating factor vasoconstriction of dog kidney. Inhibition by alprazolam.
    Baer PG; Cagen LM
    Hypertension; 1987 Mar; 9(3):253-60. PubMed ID: 3818022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal vascular and sympathetic nerve responses to hypotension induced by platelet-activating factor in anesthetized dogs.
    Matsuda Y; Shibamoto T; Hayashi T; Saeki Y; Yamaguchi Y; Tanaka S; Koyama S
    Eur J Pharmacol; 1993 Dec; 250(3):341-7. PubMed ID: 8112393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-activating factor and solute transport processes in the kidney.
    Handa RK; Strandhoy JW; Giammattei CE; Handa SE
    Am J Physiol Renal Physiol; 2003 Feb; 284(2):F274-81. PubMed ID: 12529272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF.
    Kasuya Y; Masuda Y; Shigenobu K
    Can J Physiol Pharmacol; 1984 Apr; 62(4):457-9. PubMed ID: 6733593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular effects of platelet-activating factor in lambs: role of cyclo- and lipoxygenase.
    Toga H; Hibler S; Ibe BO; Raj JU
    J Appl Physiol (1985); 1992 Dec; 73(6):2559-66. PubMed ID: 1490969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs.
    Tanaka S; Kasuya Y; Masuda Y; Shigenobu K
    J Pharmacobiodyn; 1983 Nov; 6(11):866-73. PubMed ID: 6668545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of platelet activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat.
    Goldstein BM; Gabel RA; Huggins FJ; Cervoni P; Crandall DL
    Life Sci; 1984 Sep; 35(13):1373-8. PubMed ID: 6482659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats.
    Sirén AL; Feuerstein G
    Am J Physiol; 1989 Jul; 257(1 Pt 2):H25-32. PubMed ID: 2546449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional haemodynamic effects of platelet activating factor in the rat.
    King KA; Lim SL; Pang CC
    Eur J Pharmacol; 1995 Aug; 281(2):187-93. PubMed ID: 7589206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular and renal action of platelet-activating factor in anesthetized dogs.
    Vemulapalli S; Chiu PJ; Barnett A
    Hypertension; 1984; 6(4):489-93. PubMed ID: 6378787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide mediates the inhibitory action of platelet-activating factor on angiotensin II-induced renal vasoconstriction, in vivo.
    Handa RK; Strandhoy JW
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1486-91. PubMed ID: 8667214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAF increases hepatic vascular resistance and glycogenolysis in vivo.
    Hines KL; Braillon A; Fisher RA
    Am J Physiol; 1991 Mar; 260(3 Pt 1):G471-80. PubMed ID: 1848410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor.
    Filep JG; Sirois MG; Rousseau A; Fournier A; Sirois P
    Br J Pharmacol; 1991 Dec; 104(4):797-804. PubMed ID: 1667286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-activating factor mediates endotoxin-induced acute renal insufficiency in rats.
    Wang J; Dunn MJ
    Am J Physiol; 1987 Dec; 253(6 Pt 2):F1283-9. PubMed ID: 2827506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal allograft platelet activating factor synthesis during acute cellular rejection.
    Mangino MJ; Anderson CB; Murphy MK; Turk J
    J Lipid Mediat; 1991; 4(1):69-81. PubMed ID: 1893087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PAF on isolated rat airways perfused with blood-free solution.
    Munoz NM; Kirchhoff CF; Strek ME; Blumenthal RN; Leff AR
    Am J Physiol; 1991 Apr; 260(4 Pt 1):L260-7. PubMed ID: 2018147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.